Cargando…

Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program

Ipilimumab, a fully human, recombinant, monoclonal antibody to cytotoxic T-lymphocyte antigen 4 improves overall survival (OS) in previously treated and untreated metastatic melanoma. This retrospective analysis reports data gathered by a questionnaire on the demographics, outcomes, and toxicity of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berrocal, Alfonso, Arance, Ana, Lopez Martin, Jose Antonio, Soriano, Virtudes, Muñoz, Eva, Alonso, Lorenzo, Espinosa, Enrique, Lopez Criado, Pilar, Valdivia, Javier, Martin Algarra, Salvador
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2014
Materias:	ORIGINAL ARTICLES: Clinical research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4457498/ https://www.ncbi.nlm.nih.gov/pubmed/25046550 http://dx.doi.org/10.1097/CMR.0000000000000108

Ejemplares similares

Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma – Prima study
por: Espinosa, Enrique, et al.
Publicado: (2016)

SEOM guidelines for the management of Malignant Melanoma 2015
por: Berrocal, A., et al.
Publicado: (2015)

Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy
por: Chiarion-Sileni, V, et al.
Publicado: (2014)

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP)
por: Ascierto, Paolo Antonio, et al.
Publicado: (2013)

SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry
por: Gonzalez-Cao, Maria, et al.
Publicado: (2022)

Ipilimumab in Pretreated Patients With Advanced Malignant Melanoma: Results of the South African Expanded-Access Program
por: Rapoport, Bernardo L., et al.
Publicado: (2016)

Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
por: Dalle, Stéphane, et al.
Publicado: (2021)

SEOM clinical guideline for the management of malignant melanoma (2017)
por: Berrocal, A., et al.
Publicado: (2017)

Sequence of therapies for advanced BRAFV600E/K melanoma
por: Gonzalez-Cao, Maria, et al.
Publicado: (2023)

Dabrafenib plus trametinib for compassionate use in metastatic melanoma: A STROBE-compliant retrospective observational postauthorization study
por: Martín Algarra, Salvador, et al.
Publicado: (2017)

Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients
por: S. Ahmad, Saif, et al.
Publicado: (2015)

Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma
por: Bjoern, Jon, et al.
Publicado: (2017)

Ipilimumab: Melanoma and beyond
por: Patel, Vishal, et al.
Publicado: (2011)

COVID-19 in melanoma patients: Results of the Spanish Melanoma Group Registry, GRAVID study
por: Gonzalez-Cao, Maria, et al.
Publicado: (2021)

Effects of Ipilimumab on expanded tumor infiltrating lymphocytes in patients with stage IV malignant melanoma
por: Bjørn, Jon, et al.
Publicado: (2013)

Correction: Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma
por: Bjoern, Jon, et al.
Publicado: (2018)

Ipilimumab cystic hypophysitis mimicking metastatic melanoma
por: Wallace, John, et al.
Publicado: (2018)

Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme
por: Chiarion Sileni, Vanna, et al.
Publicado: (2014)

Use of ipilimumab in the treatment of melanoma
por: Acharya, Utkarsh H, et al.
Publicado: (2013)

Ipilimumab-Induced Neutropenia in Melanoma
por: Ban-Hoefen, Makiko, et al.
Publicado: (2016)

Frequency and Characteristics of Familial Melanoma in Spain: The FAM-GEM-1 Study
por: Márquez-Rodas, Iván, et al.
Publicado: (2015)

Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study)
por: McArthur, Grant A., et al.
Publicado: (2017)

Life-threatening colitis and complete response with ipilimumab in a patient with metastatic BRAF-mutant melanoma and rheumatoid arthritis
por: Aya, Francisco, et al.
Publicado: (2016)

Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma
por: Jeter, Joanne M., et al.
Publicado: (2012)

Ipilimumab in patients with melanoma and autoimmune disease
por: Kyi, Chrisann, et al.
Publicado: (2014)

Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme
por: Altomonte, Maresa, et al.
Publicado: (2013)

Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)
por: Gonzalez-Cao, Maria, et al.
Publicado: (2021)

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
por: Chesney, Jason, et al.
Publicado: (2019)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Ipilimumab for advanced melanoma: A pharmacologic perspective
por: Trinh, Van Anh, et al.
Publicado: (2013)

Ipilimumab and radiation therapy for melanoma brain metastases
por: Silk, Ann W, et al.
Publicado: (2013)

Nivolumab plus ipilimumab in the treatment of advanced melanoma
por: Tsai, Katy K., et al.
Publicado: (2015)

Emerging options for the treatment of melanoma – focus on ipilimumab
por: Roddie, Claire, et al.
Publicado: (2014)

Adjuvant Ipilimumab in High-Risk Uveal Melanoma
por: Fountain, Eric, et al.
Publicado: (2019)

Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
por: Nyakas, M., et al.
Publicado: (2019)

Pseudo-Progression of Melanoma Treated with Nivolumab/Ipilimumab: A Case Report
por: Velazquez, Adan Martin Cuevas, et al.
Publicado: (2023)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Profile of ipilimumab and its role in the treatment of metastatic melanoma
por: Patel, Sapna P, et al.
Publicado: (2011)

Ipilimumab in the treatment of metastatic melanoma: management of adverse events
por: Della Vittoria Scarpati, Giuseppina, et al.
Publicado: (2014)

Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
por: Wang, Wenshi, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_cp6crtrmffbhakaoadbid8kpfb